Understand the source comparison
Best Peptides for PCOS: Mechanism Comparison
Tirzepatide Dual GLP-1/GIP agonist. Reduces insulin, slows gastric emptying Strong (Phase 3 RCT, n=412) Insulin-resistant, BMI ≥27 5–15mg weekly SC GI side effects during titration (35% nausea rate) Semaglutide GLP-1 agonist. Improves insulin sensitivity, appe
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide
- Dual GLP-1/GIP agonist. Reduces insulin, slows gastric emptying
- Strong (Phase 3 RCT, n=412)
- Insulin-resistant, BMI ≥27
- 5–15mg weekly SC
- GI side effects during titration (35% nausea rate)
- Semaglutide
- GLP-1 agonist. Improves insulin sensitivity, appetite suppression
- Strong (multiple Phase 3 trials)
- Metabolic PCOS, overweight/obese
- 0.25–2.4mg weekly SC
- Slower androgen reduction than tirzepatide
- Thymosin Alpha-1 (Thymalin)
- Immune modulation. Suppresses inflammatory cytokines, restores Treg function
- Moderate (pilot study, n=68)
- Lean PCOS, elevated CRP/IL-6
- 1.6mg twice weekly SC
- Does not address insulin resistance or hyperandrogenism directly
- MK-677 (Ibutamoren)
- GH secretagogue. Increases IGF-1, enhances lipolysis
- Moderate (observational, n=42)
- Visceral obesity, low IGF-1
- 25mg daily oral
- Increases appetite via ghrelin activation
- CJC-1295/Ipamorelin
- GHRH/GHRP combination. Pulsatile GH release
- Weak (case reports only)
- Body composition focus, metabolic PCOS
- 100–200mcg each, 5–6x/week SC
- Thin evidence base, complex dosing schedule
- Professional Assessment
- GLP-1 agonists (tirzepatide, semaglutide) have the strongest clinical evidence for insulin-resistant PCOS. Thymosin peptides address inflammatory phenotypes GLP-1s miss. Growth hormone secretagogues improve metabolic markers but require careful dietary management. No single peptide addresses all PCOS pathways. Combination therapy targeting both insulin resistance and inflammation produces the most consistent ovulatory improvement.